PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
-0.49%
Cost reduction while TRAW shows 0.00% growth. Joel Greenblatt would examine competitive advantage.
0.49%
Positive growth while TRAW shows decline. John Neff would investigate competitive advantages.
No Data
No Data available this quarter, please select a different quarter.
-36.64%
R&D reduction while TRAW shows 91320.59% growth. Joel Greenblatt would examine competitive risk.
-70.64%
G&A reduction while TRAW shows 61301.60% growth. Joel Greenblatt would examine efficiency advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-54.90%
Operating expenses reduction while TRAW shows 75603.42% growth. Joel Greenblatt would examine advantage.
-54.90%
Both companies reducing total costs. Martin Whitman would check industry trends.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing D&A. Martin Whitman would check industry patterns.
54.90%
EBITDA growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
54.90%
Operating income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
-10.71%
Other expenses reduction while TRAW shows 1151.26% growth. Joel Greenblatt would examine advantage.
56.85%
Pre-tax income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
56.85%
Net income growth while TRAW declines. John Neff would investigate advantages.
No Data
No Data available this quarter, please select a different quarter.
56.86%
EPS growth while TRAW declines. John Neff would investigate advantages.
56.86%
Diluted EPS growth while TRAW declines. John Neff would investigate advantages.
-0.00%
Share count reduction while TRAW shows 129.98% change. Joel Greenblatt would examine strategy.
-0.00%
Diluted share reduction while TRAW shows 129.98% change. Joel Greenblatt would examine strategy.